Earlier this month Biogen released results from its recent Phase 2B study of BAN2401. BAN2401 is an anti-amyloid beta protofibril antibody being developed for Alzheimer’s disease in collaboration with Eisai. Efficacy of BAN2401 was analyzed after 18 months of administration. Results were encouraging, showing statistical significance in the slowing of disease progression and in reduction...more »...
GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has partnered with Michael Szulczewski, who successfully co-founded the imaging company Prairie Technologies, Inc. Their complementary skills in academia and industry provide a solid basis for success in this new venture.
GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery…more »